GlassScriptPhysician profile
Vivek J Goswami
NPI 1689734113
$322,143.13
in general payments reported to CMS, 2019-2025
45 companies · $87K in 2025
The $87K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163K · 2020: $20K · 2021: $9,485 · 2022: $5,811 · 2023: $14K · 2024: $23K · 2025: $87K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $106K · Travel and Lodging: $9,443 · Food and Beverage: $7,915 · Consulting Fee: $18.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $106,340.31 |
| Travel and Lodging | $9,443.43 |
| Food and Beverage | $7,914.81 |
| Consulting Fee | $18.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $136,809.41 | 2019-2024 | |
| Novo Nordisk INC | $83,691.53 | 2021-2025 | Ozempic, Wegovy |
| Amgen INC. | $74,937.57 | 2019-2025 | Repatha, Repatha |
| Astellas Pharma US INC | $20,225.05 | 2019-2023 | Lexiscan |
| Novartis Pharmaceuticals Corporation | $1,353.69 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $876.65 | 2019-2025 | Evkeeza, Praluent |
| Esperion Therapeutics, INC. | $446.84 | 2020-2025 | Nexletol |
| Inari Medical, INC. | $409.07 | 2024-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $398.33 | 2019-2023 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $370.24 | 2019-2025 | Camzyos, Eliquis |
| Vital Connect, INC | $321.19 | 2022-2025 | Vitalpatch Rtm |
| Abbott Laboratories | $295.37 | 2022-2025 | Cardiomems |
| Janssen Pharmaceuticals, INC | $251.10 | 2019-2024 | Xarelto |
| Arbor Pharmaceuticals, INC. | $249.15 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $219.75 | 2021-2023 | Optimizer |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivek Goswami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.